The Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.
Acc Chem Res. 2024 Jul 2;57(13):1870-1884. doi: 10.1021/acs.accounts.4c00262. Epub 2024 Jun 14.
ConspectusThe bis-tetrahydroisoquinoline (bis-THIQ) natural products represent a medicinally important class of isoquinoline alkaloids that exhibit broad biological activities with particularly potent antitumor properties, as exemplified by the two U.S. FDA approved molecules trabectidin and lurbinectedin. Accordingly, other members within the bis-THIQ family have emerged as prime targets for synthetic chemists, aiming to innovate an orthogonal chemical production of these compounds. With the ability of these complementary strategies to reliably and predictably manipulate molecular structures with atomic precision, this should allow the preparation of synthetic derivatives not existing in nature as new drug leads in the development of novel medicines with desired biological functions.Beyond the biological perspective, bis-THIQ natural products also possess intricate and unique structures, serving as a source of intellectual stimulation for synthetic organic chemists. Within our laboratory, we have developed an integrated program that combines reaction development and target-directed synthesis, leveraging the architecturally complex molecular framework of bis-THIQ natural products as a driving force for the advancement of novel reaction methodologies. In this Account, we unveil our synthetic efforts in a comprehensive story, describing how our synthetic strategy toward bis-THIQ natural products, specifically jorunnamycin A and jorumycin, has evolved over the course of our studies through our key transformations comprising (a) the direct functionalization of isoquinoline -oxide to prepare the bis-isoquinoline (bis-IQ) intermediate, (b) the diastereoselective and enantioselective isoquinoline hydrogenation to forge the pentacyclic skeleton of the natural product, and (c) the late-stage oxygenation chemistry to adjust the oxidation states of the A- and E-rings. First, we detail our plan in utilizing the aryne annulation strategy to prepare isoquinoline fragments for the bis-THIQ molecules. Faced with unpromising results in the direct C-H functionalization of isoquinoline -oxide, we lay out in this Account our rationale behind the design of each isoquinoline coupling partner to overcome these challenges. Additionally, we reveal the inspiration for our hydrogenation system, the setup of our pseudo-high-throughput screening, and the extension of the developed hydrogenation protocols to other simplified isoquinolines.In the context of non-natural bis-THIQ molecules, we have successfully adapted this tandem coupling/hydrogenation approach in the preparation of perfluorinated bis-THIQs, representing the first set of electron-deficient non-natural analogues. Finally, we include our unsuccessful late-stage oxygenation attempts prior to the discovery of the Pd-catalyzed C-O cross-coupling reaction. With this full disclosure of the chemistry developed for the syntheses of bis-THIQs, we hope our orthogonal synthetic tactics will provide useful information and serve as an inspiration for the future development of bis-THIQ pharmaceuticals.
概要双四氢异喹啉(双-THIQ)天然产物代表了一类具有重要医学意义的异喹啉生物碱,具有广泛的生物活性,特别是具有很强的抗肿瘤特性,美国食品和药物管理局批准的两种分子 trabectidin 和 lurbinectedin 就是例证。因此,双-THIQ 家族的其他成员已成为合成化学家的主要目标,旨在创新这些化合物的正交化学生产。这些互补策略能够以原子精度可靠且可预测地操纵分子结构,这应该允许制备自然界中不存在的合成衍生物,作为具有所需生物学功能的新型药物的新药物先导。
除了生物学角度外,双-THIQ 天然产物还具有复杂而独特的结构,为合成有机化学家提供了灵感来源。在我们的实验室中,我们开发了一个集成的计划,该计划结合了反应开发和靶向合成,利用双-THIQ 天然产物的架构复杂的分子框架作为推进新反应方法的驱动力。在本报告中,我们全面介绍了我们的合成工作,描述了我们的合成策略如何通过我们的关键转化(a)直接官能化异喹啉-氧化物以制备双异喹啉(双-IQ)中间体,(b)对映选择性异喹啉氢化以形成天然产物的五环骨架,以及(c)后期的氧化化学来调整 A-和 E-环的氧化态,在我们的研究过程中针对双-THIQ 天然产物(特别是jorunnamycin A 和 jorumycin)不断发展。首先,我们详细介绍了利用芳炔环加成策略制备双-THIQ 分子的异喹啉片段的计划。在直接 C-H 官能化异喹啉-氧化物方面遇到了不理想的结果,我们在本报告中详细说明了每个异喹啉偶联伙伴的设计背后的原理,以克服这些挑战。此外,我们还揭示了我们的氢化系统的灵感来源,伪高通量筛选的设置以及开发的氢化方案在其他简化异喹啉中的扩展。
在非天然双-THIQ 分子的背景下,我们成功地将这种串联偶联/氢化方法应用于全氟双-THIQ 的制备中,这是第一组电子缺电子的非天然类似物。最后,我们包括在发现 Pd 催化的 C-O 交叉偶联反应之前我们不成功的后期氧化尝试。通过全面披露用于双-THIQ 合成的化学,我们希望我们的正交合成策略将提供有用的信息,并为双-THIQ 药物的未来发展提供灵感。